Cited by 4,233Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsRadiation Therapy and Dosimetry

The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index.

Nanoparticle therapeutics: an emerging treatment modality for cancer

Davis, Mark E., Chen, Zhuo, Shin, Dong M.·2008·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

Nanoparticles--particles in the size range 1-100 nm--are emerging as a class of therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can show enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumours and active cellular uptake. Here, we highlight the features of nanoparticle therapeutics that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While large numbers of preclinical studies have been published, the emphasis here is placed on preclinical and clinical studies that are likely to affect clinical investigations and their implications for advancing the treatment of patients with cancer.

Integrity signals

Registry

Crossref · 10.1038/nrd2614

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,978
Self-citation
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201
Self-citation
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1958 · Cited by 1,956
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc903 · Cited by 1,648
Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models
Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., Marks, J. D., Benz, C. C., & Park, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4199 · Cited by 1,129
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 911
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
Bartlett, D. W., Su, H. C., Hildebrandt, I. J., Weber, W., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 820
Self-citation
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 704
Self-citation
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Toxicity and Tissue Distribution of Magnetic Nanoparticles in Mice
Kim, J. S., Yoon, T., Yu, K. N., Kim, B. G., Park, S. J., Kim, H. W., Lee, K. H., Park, S. B., Lee, J.-K., & Cho, M. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfj027 · Cited by 643
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 601
The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery Platform
Hong, S., Leroueil, P. R., Majoros, I., Orr, B. G., Baker, J. R., & Holl, M. M. B. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.11.015 · Cited by 585
Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor
Lee, E. S., Na, K., & Bae, Y. H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.12.018 · Cited by 577
Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma
Hu‐Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 568
Self-citation
Functionalized micellar systems for cancer targeted drug delivery
Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R.-E., & Mason, D. Y. (1983) · Journal of Clinical Pathology · doi:10.1136/jcp.36.5.539 · Cited by 530
Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
Sparreboom, A., Scripture, C. D., Trieu, V. N., Williams, P. J., De, T., Yang, A. J., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 506
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei‐Tsao, D. D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizón, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability
Venturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 463
Polymer-drug conjugates: Recent development in clinical oncology
Li, C., & Wallace, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.009 · Cited by 438
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Complement activation and protein adsorption by carbon nanotubes
Salvador-Morales, C., Emmanuel Flahaut, B., Sim, E., Sloan, J., HGREEN, M., & Sim, R. B. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.02.006 · Cited by 433
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications
Wang, Y.-S., Youngster, S. K., Grace, M. J., Bausch, J. N., Bordens, R. W., & Wyss, D. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00027-3 · Cited by 420
Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting
Peracchia, M. T., Fattal, E., Desmaële, D., Besnard, M., Noël, J. P., Gomis, J.-M., Appel, M., d’Angelo, J., & Couvreur, P. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00063-2 · Cited by 400
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 395
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 390
Self-citation
Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display
Montet, X., Funovics, M. A., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer
Sahoo, S. K., Ma, W., & Labhasetwar, V. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
Holmes, F. A., Jones, S. E., O’Shaughnessy, J., Vukelja, S. J., George, T. K., Savin, M., Richards, D., Glaspy, J. A., Meza, L. A., Cohen, G. I., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf130 · Cited by 291
Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles
Vauthier, C. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.005 · Cited by 289
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 287
Self-citation
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1668 · Cited by 287
The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)
Molineux, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452613 · Cited by 285
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Selective Tumor Cell Targeting Using Low-Affinity, Multivalent Interactions
Carlson, C. B., Mowery, P., Owen, R. M., Dykhuizen, E. C., & Kiessling, L. L. (2007) · ACS Chemical Biology · doi:10.1021/cb6003788 · Cited by 270
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh092 · Cited by 253
Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome
Suzuki, R., 知子, 滝., Kuwata, Y., Mutoh, M., Ishiguro, N., Utoguchi, N., Shinohara, A., Eriguchi, M., Yanagië, H., & Maruyama, K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.010 · Cited by 252
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer
Modok, S., Mellor, H. R., & Callaghan, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.009 · Cited by 241
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
Zamboni, W. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1895 · Cited by 235
The clinical efficacy of poly(ethylene glycol)-modified proteins
Fuertges, F., & Abuchowski, A. (1990) · Journal of Controlled Release · doi:10.1016/0168-3659(90)90127-f · Cited by 227
Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab -Paclitaxel
Gardner, E. R., Dahut, W. L., Scripture, C. D., Jones, J., Aragon-Ching, J. B., Desai, N., Hawkins, M. J., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4592 · Cited by 226
Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models
Schluep, T., Hwang, J., Cheng, J., Heidel, J. D., Bartlett, D. W., Hollister, B. A., & Davis, M. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1566 · Cited by 222
Self-citation
Preclinical evaluation of polymer-bound doxorubicin
Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S. R., Hume, I. C., Ulbrich, K., Strohalm, J., Šubr, V., Spreafico, F., et al. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90088-9 · Cited by 187
Clinical Pharmacokinetics of Topotecan
Herben, V. M. M., Huinink, W. W. T. B., & Beijnen, J. H. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631020-00001 · Cited by 181
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine
Julyan, P. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00124-2 · Cited by 180
Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
Northfelt, D., Dezube, B. J., Thommes, J. A., Levine, R., Roenn, J. H. V., Dosik, G. M., Ríos, A., Krown, S. E., DuMond, C., & Mamelok, R. D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.653 · Cited by 170
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
Seymour, L. W., Ulbrich, K., Steyger, P. S., Brereton, M., Šubr, V., Strohalm, J., & Duncan, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.363 · Cited by 164
Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate
Singer, J. W., Baker, B., de Vries, P., Kumar, A., Shaffer, S., Vawter, E., Bolton, M., & Garzone, P. D. (2004) · Advances in experimental medicine and biology · doi:10.1007/0-306-47932-x_6 · Cited by 156
Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing
Bartlett, D. W., & Davis, M. E. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21285 · Cited by 154
Self-citation
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study
Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., & Buchanan, G. R. (2000) · Blood · doi:10.1182/blood.v96.5.1709 · Cited by 152
Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells
Zhou, Y., Drummond, D. C., Zou, H., Hayes, M. E., Adams, G. P., Kirpotin, D. B., & Marks, J. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.011 · Cited by 151
Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice
Schluep, T., Cheng, J., Khin, K. T., & Davis, M. E. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0091-7 · Cited by 142
Self-citation
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane
Singer, J. W., Shaffer, S. A., Baker, B., Bernareggi, A., Stromatt, S. C., Nienstedt, D., & Besman, M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200503000-00003 · Cited by 138
Effect of Particle Size and Charge on the Disposition of Lipid Carriers After Intratumoral Injection into Tissue-isolated Tumors
Nomura, T., Koreeda, N., Yamashita, F., Takakura, Y., & Hashida, M. (1998) · Pharmaceutical Research · doi:10.1023/a:1011921324952 · Cited by 135
A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies
Rowinsky, E. K., Rizzo, J. D., Ochoa, L., Takimoto, C. H. M., Forouzesh, B., Schwartz, G. H., Hammond, L. A., Patnaik, A., Kwiatek, J., Goetz, A. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.143 · Cited by 132
Pegylated liposomal doxorubicin in ovarian cancer.
Green, A. E., & Rose, P. G. (2006) · PubMed Central · Cited by 128
Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system
Chen, M. Y., Hoffer, A., Morrison, P. F., Hamilton, J. F., Hughes, J. A., Schlageter, K. S., Lee, J., Kelly, B. R., & Oldfield, E. H. (2005) · Journal of neurosurgery · doi:10.3171/jns.2005.103.2.0311 · Cited by 118
Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study
Bukowski, R. M., Ernstoff, M. S., Gore, M. E., Nemunaitis, J. J., Amato, R. J., Gupta, S. K., & Tendler, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.051 · Cited by 117
Designing polymer conjugates as lysosomotropic nanomedicines
Duncan, R. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350056 · Cited by 117
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
Boddy, A. V., Plummer, E. R., Todd, R., Sludden, J., Griffin, M., Robson, L., Cassidy, J., Bissett, D., Bernareggi, A., Verrill, M. W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0803 · Cited by 108
Phase I Trial of Poly- l -Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies
Homsi, J., Simon, G. R., Garrett, C. R., Springett, G. M., Conti, R. C. D., Chiappori, A., Münster, P. N., Burton, M. K., Stromatt, S. C., Allievi, C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2821 · Cited by 103
Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints
Pommier, Y. G. (2004) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011043352777 · Cited by 102
Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy
Henderson, I. C., & Bhatia, V. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.919 · Cited by 102
Resolving The Nanoparticles Paradox
Donaldson, K. (2006) · Nanomedicine · doi:10.2217/17435889.1.2.229 · Cited by 94
Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.
Tanaka, H., Satake-Ishikawa, R., Ishikawa, M., Matsuki, S., & Asano, K. (1991) · PubMed · Cited by 90
A Nanoparticle-Based Model Delivery System To Guide the Rational Design of Gene Delivery to the Liver. 2. In Vitro and In Vivo Uptake Results
Popielarski, S. R., Hu‐Lieskovan, S., French, S. W., Triche, T. J., & Davis, M. E. (2005) · Bioconjugate Chemistry · doi:10.1021/bc0501146 · Cited by 84
Self-citation
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
Thomson, A. H., Vasey, P. A., Murray, L. S., Cassidy, J., Fraier, D., Frigerio, E., & Twelves, C. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690657 · Cited by 81
Estrogen modulation of osteoclast lysosomal enzyme secretion
Kremer, M., Judd, J., Rifkin, B. R., Auszmann, J. M., & Oursler, M. J. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240570211 · Cited by 79
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
Scott, L. C., Yao, J. C., Benson, A. B., Thomas, A., Falk, S. J., Mena, R. R., Picus, J., Wright, J. R., Mulcahy, M. F., Ajani, J. A., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0746-2 · Cited by 78
Cardiac safety of liposomal anthracyclines
Batist, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0014-4 · Cited by 62
SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: A phase II window study
Armstrong, A. C., Brewer, J., Newman, C., Alakhov, V. Y., Pietrzyński, G., Campbell, S., Corrie, P. G., Ranson, M., & Valle, J. W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4080 · Cited by 55
Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time
Armstrong, D. K., & Brady, M. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7140 · Cited by 52
Targeted Anticancer Immunotoxins and Cytotoxic Agents with Direct Killing Moieties
Kawakami, K., Nakajima, O., Morishita, R., & Nagai, R. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.162 · Cited by 51
Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas
Posey, J. A., Saif, M. W., Carlisle, R. R., Goetz, A. D., Rizzo, J. D., Stevenson, S., Rudoltz, M. S., Kwiatek, J., Simmons, P., Rowinsky, E. K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0783 · Cited by 51
Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors
Nemunaitis, J. J., Cunningham, C. C., Senzer, N. N., Gray, M., Oldham, F. B., Pippen, J., Mennel, R. G., & Eisenfeld, A. J. (2005) · Cancer Investigation · doi:10.1080/07357900500359935 · Cited by 41
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
O'Brien, M. E. R. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f14a00 · Cited by 39
On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level
Pepin, X. J. H., Attali, L., Domrault, C., Gallet, S., Métreau, J. M., Reault, Y., Cardot, P. J. P., Imalalen, M., Dubernet, C., Soma, C. E., et al. (1997) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(97)00362-9 · Cited by 38
Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): Safety, pharmacogenomics, pharmacokinetics, and tumor response
Kraut, E. H., Fishman, M., LoRusso, P. M., Gordon, M. S., Rubin, E. H., Haas, A., Fetterly, G. J., Cullinan, P., Dul, J. L., & Steinberg, J. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2017 · Cited by 30
Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study
Langer, C. J., Socinski, M. A., & O'Byrne, K. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba7011 · Cited by 28
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80747-x · Cited by 18
Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma
Delman, K. A., Brown, T. D., Thomas, M., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., & Curley, S. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4139 · Cited by 17
First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors
Yen, Y., Synold, T. W., Schluep, T., Hwang, J., Oliver, J., & Davis, M. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14078 · Cited by 12
Self-citation
Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors
DAUD, A. I., Garrett, C. R., Simon, G. R., Münster, P. N., Sullivan, D. M., Stromatt, S. C., Allevi, C., & Bernareggi, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2015 · Cited by 11
Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors.
Phan, A. T., Takimoto, C. H. M., Adinin, R., Wood, L., Xiong, H. Q., Matsuno, K., Konno, S., Fujisawa, T., & Beeram, M. (2007) · Molecular Cancer Therapeutics · Cited by 11
Pegylated Liposomal Doxorubicin and Immunomodulatory Drug Combinations in Multiple Myeloma: Rationale and Clinical Experience
Chanan-Khan, A. A., & Lee, K. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.018 · Cited by 11
Pegylated recombinant human arginase (rhArg-peg 5000mw) has in vitro and in vivo anti-proliferative potential and apoptotic activities in human hepatocellular varcinoma (HCC)
Cheng, P., Lo, T. W.-H., Leung, T.-W., Lam, A. T., & Lam, W.-M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3179 · Cited by 9
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate
Todd, R., BODDY, A., Verrill, M., Sludden, J., Griffin, M., Elliott, S., Fishwick, K., Robson, L., Cassidy, J., Main, M., et al. (2001) · UCL Discovery (University College London) · doi:10.25405/ncl.34646574 · Cited by 9
Proteolysis of xyotax by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)81079-6 · Cited by 8
Multicenter phase II study of a cremophor-free polymeric micelle-formulated paclitaxel in patients (pts) with metastatic breast cancer (MBC)
Lee, K. S., Chung, H. C., Im, S., Park, Y. H., Kim, S. B., Kim, C. S., & Ro, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10520 · Cited by 5
Phase II trial of pegylated interferon (Peg-Intron) and thalidomide (Thal) in pretreated metastatic malignant melanoma
Flaherty, L. E., Heilbrun, L. K., Marsack, C., & Vaishampayan, U. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7562 · Cited by 2
Exemestane: an alternative treatment option in early breast cancer
Jassem, J. (2008) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000277607.85258.de · Cited by 1

Flagged first, then by citations

2 of the 108 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Kurtzberg, J., Moore, J. O. Scudiery, D. & Franklin, A. A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukaemias. Proc. Am. Assoc. Cancer Res. 29, 213 (1988).
Socinski, M. & Ramalingham, S. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological differences between men and women: is gender-specific therapy warranted? Chemotherapy Foundation web site [online], (2005).
Vasey, P. et al. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug–polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999).

Sorted by citations

Metal–Organic Frameworks in Biomedicine
Horcajada, P., Gref, R., Baâti, T., Allan, P. K., Maurin, G., Couvreur, P., Férey, G., Morris, R. E., & Serre, C. (2011) · Chemical Reviews · doi:10.1021/cr200256v · Cited by 4,241
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,265
Nanoparticles in Photodynamic Therapy
Lucky, S. S., Soo, K. C., & Zhang, Y. (2015) · Chemical Reviews · doi:10.1021/cr5004198 · Cited by 2,999
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,898

See all 4,233

Authors: Davis, M. E., Chen, Z., & Shin, D. M.
Affiliations: California Institute of Technology (US)
Emory University (US)
Corresponding author: Davis, Mark E.
ORCID: Davis, Mark E.
Chen, Zhuo
Shin, Dong M.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2008-09
Volume: 7
Issue: 9
Pages: 771-782
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2614
OpenAlex: W2082511916
Cited by: 4,233
References: 108
Citations by year: 2026: 68 · 2025: 134 · 2024: 165 · 2023: 143 · 2022: 171 · 2021: 217 · 2020: 224 · 2019: 260 · 2018: 316 · 2017: 340 · 2016: 364 · 2015: 383 · 2014: 385 · 2013: 332 · 2012: 268
FWCI: 7.10
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
CaltechAUTHORS (California Institute of Technology) (submittedVersion)
Funders: National Cancer Institute (U54CA119338)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords: nanotherapeutics, cancer therapy, nanomedicine, targeted drug delivery, tumor localization, cellular uptake, clinical translation, clinical trials, anticancer agents, adverse drug reactions
MeSH terms: Animals, Antineoplastic Agents, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Drug Delivery Systems, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nanoparticle therapeutics: an emerging treatment modality for cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks